Additional Notable Research Advances Presented at 2011 ASCO Annual Meeting

For Immediate Release
June 5, 2011

Susie Tappouni

CHICAGO - In addition to the abstracts featured in the official 2011 ASCO Annual Meeting Press Program, nine noteworthy studies on the prevention, screening, evaluation and management of several types of cancers were highlighted at the meeting. The 2011 ASCO Annual Meeting is being held June 3-7 at McCormick Place in Chicago.

Abstract 82085Phase III randomized, double-blind, placebo-controlled trial of soy protein and venlafaxine for treatment of hot flashes in men with prostate cancer.
Lead Author: Mara Vitolins, MD
Poster Discussion Session
Sunday, June 5
8:00 AM - 12:00 PM

Abstract 81907Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.
Lead Author: Brian Rini, MD
Oral Abstract Session
Monday, June 6
8:00 AM - 8:15 AM

Abstract 77126Prospective and observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer.
Lead Author: Michael Fisch, MD
Oral Abstract Session
Monday, June 6
11:00 AM - 11:15 AM

Abstract 82339Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
Lead Author: Maha Hussain, MD
Oral Abstract Session
Monday, June 6
1:15 - 1:30 AM

Abstract 77834Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?
Lead Author: Susan M. Domcheck, MD
Oral Abstract Session
Monday, June 6
3:15 PM - 3:30 PM

Abstract 83283PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072).Lead Author: W. T. Van der Graaf, MD
Oral Abstract Session
Monday, June 6
3:30 PM - 3:45 PM

Abstract 83975Metformin and breast cancer incidence in postmenopausal diabetic women in the Women's Health Initiative (WHI).
Lead Author: Rowan Chlebowski, MD
Oral Abstract Session
Monday, June 6
4:00 PM - 4:15 PM

Abstract 77463Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial.
Lead Author: Yung-Jue Bang, MD
Oral Abstract Session
Tuesday, June 7
10:15 AM - 10:30 AM

Abstract 78733Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.
Lead Author: John P. Neoptolemos, MD
Oral Abstract Session
Tuesday, June 7
11:45 AM - 12:00 PM

Relevant Links on ASCO's patient website, www.Cancer.Net.

Click here to download the press release.


The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who care for people with cancer. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. Patient-oriented cancer information is available at www.Cancer.Net.